1. Home
  2. PDCC vs LCTX Comparison

PDCC vs LCTX Comparison

Compare PDCC & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PDCC
  • LCTX
  • Stock Information
  • Founded
  • PDCC N/A
  • LCTX 1990
  • Country
  • PDCC
  • LCTX United States
  • Employees
  • PDCC N/A
  • LCTX 75
  • Industry
  • PDCC
  • LCTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • PDCC
  • LCTX Health Care
  • Exchange
  • PDCC NYSE
  • LCTX Nasdaq
  • Market Cap
  • PDCC 140.6M
  • LCTX 115.0M
  • IPO Year
  • PDCC N/A
  • LCTX N/A
  • Fundamental
  • Price
  • PDCC $20.50
  • LCTX $0.50
  • Analyst Decision
  • PDCC
  • LCTX Strong Buy
  • Analyst Count
  • PDCC 0
  • LCTX 4
  • Target Price
  • PDCC N/A
  • LCTX $4.75
  • AVG Volume (30 Days)
  • PDCC N/A
  • LCTX 1.9M
  • Earning Date
  • PDCC N/A
  • LCTX 11-14-2024
  • Dividend Yield
  • PDCC N/A
  • LCTX N/A
  • EPS Growth
  • PDCC N/A
  • LCTX N/A
  • EPS
  • PDCC N/A
  • LCTX N/A
  • Revenue
  • PDCC N/A
  • LCTX $8,719,000.00
  • Revenue This Year
  • PDCC N/A
  • LCTX N/A
  • Revenue Next Year
  • PDCC N/A
  • LCTX $123.52
  • P/E Ratio
  • PDCC N/A
  • LCTX N/A
  • Revenue Growth
  • PDCC N/A
  • LCTX N/A
  • 52 Week Low
  • PDCC N/A
  • LCTX $0.50
  • 52 Week High
  • PDCC N/A
  • LCTX $1.61
  • Technical
  • Relative Strength Index (RSI)
  • PDCC N/A
  • LCTX 22.34
  • Support Level
  • PDCC N/A
  • LCTX $0.80
  • Resistance Level
  • PDCC N/A
  • LCTX $0.97
  • Average True Range (ATR)
  • PDCC 0.00
  • LCTX 0.07
  • MACD
  • PDCC 0.00
  • LCTX -0.04
  • Stochastic Oscillator
  • PDCC 0.00
  • LCTX 0.70

About PDCC PEARL DIVER CREDIT COMPANY INC

PEARL DIVER CREDIT COMPANY INC is a non-diversified closed ended management investment company.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Share on Social Networks: